Mayo Clinic
This is an imaging study of patients with mild Alzheimer's disease receiving amyloid-targeting therapy and under the care of neurologists at Mayo Clinic in Rochester, MN.
Inclusion Criteria * Age 50-90 years * Male or female * Mild cognitive impairment due to AD or mild AD * Amyloid positive via CSF or PET * Meets other eligibility criteria for anti-amyloid immunotherapy * Subject or delegate provides informed consent Exclusion Criteria * Subjects unable to lie down without moving for 10 minutes. * Women who are pregnant or cannot stop breast feeding for 24 hours. * Claustrophobic patients unable to tolerate the scans (no sedation can be offered).
Subjects will receive two Tau PET (18F--AV-1451) brain scans with approximately 10 mCi (370 MBq) (+/- 10%mCi) of 18F-AV-1451. Images will be collected for a 20-minute acquisition between 80-100 minutes after injection. Tau PET scans will occur at baseline and 12-18 months after completing anti-amyloid immunotherapy treatment..
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.